{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:45:59Z","timestamp":1766040359550,"version":"3.48.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The management of multiple sclerosis (MS) in patients with significant comorbidities such as severe asthma presents unique therapeutic challenges. We report a case of successful combined biologic therapy with ofatumumab and mepolizumab in a patient with relapsing MS and pre-existing severe eosinophilic asthma, highlighting the feasibility and safety of dual biologic therapy. To our knowledge, this is the first report of concomitant use of ofatumumab and mepolizumab in a patient with MS and severe eosinophilic asthma, documenting the safety of a non-standard combination strategy in a real-world clinical scenario.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1634477","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:42:32Z","timestamp":1766040152000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined biologic therapy targeting B cells and eosinophils in relapsing multiple sclerosis and severe asthma: a case report of ofatumumab and mepolizumab"],"prefix":"10.3389","volume":"16","author":[{"given":"Aurora","family":"Zangh\u00ec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola Sofia","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Rutigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.05.003","article-title":"Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives","volume":"18","author":"D\u2019Amico","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105546","article-title":"Asthma and chronic obstructive pulmonary disease (COPD) in people with multiple sclerosis: A systematic review and meta-analysis","volume":"85","author":"Ghoshouni","year":"2024","journal-title":"Multiple Sclerosis Related Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2377-12-55","article-title":"Brief International Cognitive Assessment for MS (BICAMS): international standards for validation","volume":"12","author":"Benedict","year":"2012","journal-title":"BMC Neurology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.05.016","article-title":"Asthma control in elderly asthmatics. An Italian observational study","volume":"108","author":"Milanese","year":"2014","journal-title":"Respir Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5826\/mrm.2024.985","article-title":"Impact of biological therapies on laboratory outcomes and FEV1 in patients with severe eosinophilic asthma with chronic rhinosinusitis: a real-life study from Saudi Arabia","volume":"19","author":"Abu Elhassan","year":"2024","journal-title":"Multidiscip Respir Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/neurosci3030036","article-title":"Cognitive relapse in multiple sclerosis: new findings and directions for future research","volume":"3","author":"Weinstock","year":"2022","journal-title":"NeuroSci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/diagnostics11030464","article-title":"Isolated cognitive decline in neurologically stable patients with multiple sclerosis","volume":"11","author":"Motyl","year":"2021","journal-title":"Diagnostics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1197195","article-title":"Etiology, effects and management of comorbidities in multiple sclerosis: recent advances","volume":"14","author":"Marrie","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1756286419836571","DOI":"10.1177\/1756286419836571","article-title":"Risks and risk management in modern multiple sclerosis immunotherapeutic treatment","volume":"12","author":"Klotz","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"B12","article-title":"Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift","volume":"5","author":"Katerina","year":"2019","journal-title":"RMD Open"},{"key":"B13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0065-2776(08)01006-7","article-title":"Interleukin 5 in the link between the innate and acquired immune response","volume":"101","author":"Takatsu","year":"2009","journal-title":"Adv Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.04.001","article-title":"IL-5 and eosinophilia","volume":"20","author":"Takatsu","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10494","article-title":"Dual biologic therapy in patients with rheumatoid arthritis and psoriatic arthritis","volume":"14","author":"Furer","year":"2023","journal-title":"Rambam Maimonides Med J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i12.2621","article-title":"Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease","volume":"11","author":"McCormack","year":"2023","journal-title":"World J Clin Cases"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1634477\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:42:39Z","timestamp":1766040159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1634477\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":16,"alternative-id":["10.3389\/fimmu.2025.1634477"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1634477","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"1634477"}}